The news that BiH has medicine that helps in the treatment of Covid-19 patients echoed the region. The medicine is called Enkorten and it is made by the local Bosnalijek drug company, Anadolu News Agency reported Friday adding that clinical trials in hospitals in Sarajevo, Banja Luka, Mostar, Zenica and Travnik showed encouraging results.

In an interview with Anadolu Agency, Bosnalijek General Manager Nedim Uzunović confirmed that the clinical trial showed that Encorten is effective and safe for use in moderately severe Covid-19 infection in hospital conditions and that it significantly helps and accelerates the recovery of these patients. The research, he reveals, also showed very good tolerability to the drug.

“The clinical study is over and we are extremely pleased with the results whose indicators are really encouraging. It's important to note that this is not a cure for Covid-19, but that the drug Enkorten can significantly help in the treatment of patients in whom coronavirus causes the so-called cytokine storm, and it is precisely these moderately severe cases that most often end up in the hospital and in which the cytokine storm leads to an even more serious condition, and often death,” Uzunovic said.

He confirmed that the drug was registered in Bosnia for the treatment of multiple sclerosis and considering it is an immunomodulator noting that it was previously approved for its role in modifying the production of cytokines as one of the ways in which to modulate the immune response. This was the basis for the beginning of clinical trials for Covid-19 treatment.

“We hope the medicine will help as many patients with Covid-19 and I'm really proud that we, as a local company, offered a response to this difficult situation,” the Bosnalijek General Manager concluded.